StrokeHome RehabGymNCT06406569
A Qualitative and Usability Evaluation of Advanced Technologies for Home Upper Limb Neurorehabilitation Post-stroke
A study testing H-Man Robot, ReHandyBot and MyoPanda in people with Stroke, run by Tan Tock Seng Hospital at 1 site in Singapore.
Trial summary
Due to limited resources such as the low therapist to patient ratio or high costs associated to rehabilitation therapy, providing higher therapy dose to patients after discharge is highly challenging. Read more about this study
- Who is it for?
- Ages 21 to 80 years
- Conditions the study is for
- Stroke
- What is being tested?
- H-Man Robot, ReHandyBot and MyoPanda
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 29 participants
- Where
- 1 siteSingapore
- Study dates
- 31 Jul 2024to 5 Jun 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Clinical stroke (ischaemic or haemorrhagic) confirmed by admitting doctors and CT, CT angiography or MRI brain imaging
- Age 21 to 80 years, both males and females
- At least 28 days post-stroke
- Upper limb motor impairment of Fugl-Meyer Assessment (FMA) scale 20 to 50
- Montreal Cognitive Assessment (MoCA) > 21/30
- Ability to sit supported and continuously for 60 minutes
- Stable home abode with enough space to place technologies
- Has a carer/next of kin to supervise home-based exercises
Who cannot join
- Functional impairment of the upper limb due to other pathologies
- Medical conditions incompatible with research participation: uncontrolled medical illnesses (hypertension or diabetes, ischaemic heart disease, congestive heart failure, bronchial asthma, severe /untreated depression, agitation, end stage renal/liver/heart/lung failure, unresolved cancers)
- Anticipated life expectancy of less than 6 months
- Pacemakers and other active implants
- Active seizures within 3 months
- Local factors potentially worsened by intensive technology-aided upper-limb therapy and computer-based training:
Show all 13Show fewer
- Spasticity - modified Ashworth Scale MAS > 2 of any upper limb muscle groups
- Severe pain in affected arm - Visual Analogue Scale for pain VAS > 5/10
- Skin wounds
- Cognitive impairment precluding study participation
- Severe visual impairment or visual neglect affecting ability to use technologies
- History of dementia, depression or behavioural problems
- Pregnant or lactating females will not be allowed to participate
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Home RehabGym: a Qualitative and Usability Evaluation of Advanced Technologies for Home Upper Limb Neurorehabilitation Post-stroke
Due to limited resources such as the low therapist to patient ratio or high costs associated to rehabilitation therapy, providing higher therapy dose to patients after discharge is highly challenging. This often results in non-use of the impaired limb as a result of the decreased therapy dose, causing partial loss of the functional improvements previously gained during early rehabilitation.
In this study, the investigators plan to pilot the HomeRehab Gym concept via the deployment of three rehabilitation devices at patients' homes: MyoPanda, H-Man and ReHandyBot.
Read the detailed description
Previous research has proven that technology-aided upper limb rehabilitation is non-inferior in terms of feasibility and efficacy when compared to conventional therapy in stroke patients. These rehabilitation devices can be set up as a 'rehabilitation gym' (RehabGym), where patients can interact with several devices that target different body and rehabilitation domains and, thus allows for a holistic and complementary therapy.
Despite recent studies having shown that training with a RehabGym under reduced supervision in a hospital is not only feasible but also equally beneficial in terms of clinical outcomes, however, a RehabGym has never been set up at a patient's home to the best of our knowledge.
This study aims to investigate the feasibility and safety of a RehabGym at home concept using three different upper-limb technologies (H-Man, ReHandyBot, MyoPanda) that are established, clinically tested and allow for on-demand therapy. Objective measures of clinical efficacy will also be examined, and cost-analysis to determine the economic feasibility of a commercial implementation of RehabGym at home in the future will be performed.
- Conditions
- Stroke
- Being tested
- H-Man Robot, ReHandyBot, MyoPanda
- Keywords
- Technology-aided, Upper limb rehabilitation
- Medical subject headings
- Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
H-Man RobotDevice
The HMAN is certified as a CE class 2A upper limb rehabilitation robot suitable for hospital, clinic and home-based use in 2020 by Health Sciences Authority, Singapore. It has since been employed in post-stroke neurorehabilitation therapy and assessment of sensorimotor functions in stroke patients.
ReHandyBotDevice
ReHandyBot is the portable version of ReHapticKnob a robot developed at ETH Zurich that provides neurocognitive therapy, focusing on hand opening and closing movements as well as prono-supination of the forearm.
MyoPandaDevice
MyoPanda is a passive wrist/hand device which patients use to train the hand and wrist function by controlling a virtual avatar with EMG activity measures.
| Study group | Role | What they receive |
|---|---|---|
| Home Robotics Upper Limb Training | Other | The patients will first familiarize in the clinic with the 3 devices (H-MAN, ReHandyBot and MyoPanda) with initial assistance of the therapists and then take the devices home for independent, self-administered training under caregiver supervision.
During the 6 weeks training (home phase), patients will be provided with two devices at any one time: with only the MyoPanda being used by the patient for 6 weeks. The H-MAN and ReHandyBot will stay with the patient for 3 weeks (i.e., 21 days) each. Receives: Device: H-Man Robot; Device: ReHandyBot; Device: MyoPanda |
What is being measured
The primary outcome is the main question the study is designed to answer.
Compliance Rates
Using cloud data from vendor, time (min/hours) of robot (H-Man, ReHandyBot, MyoPanda) usage
Measured: Through study's data collection period, up to 2 years.
Secondary outcomes (5)
Fugl Meyer Motor Assessment (FMA)
Change in Fugl Meyer Motor Assessment score in the affected arm, minimum 0, maximum 66, with higher scores indicating better function
Measured: Weeks 0 (baseline), 3 (mid-intervention assessment), 6 (post-intervention assessment), 12 (1st follow-up assessment), 24 (last follow-up assessment)
Action Research Arm Test (ARAT)
Functional and dexterity score for upper extremities, minimum 0, maximum 57; with higher score indicating better function
Measured: Weeks 0 (baseline), 3 (mid-intervention assessment), 6 (post-intervention assessment), 12 (1st follow-up assessment), 24 (last follow-up assessment)
System Usability Scale (SUS)
For evaluation of the different robots' (H-Man, ReHandyBot, MyoPanda) perceived usability, scaled from 1 (Strongly disagree) to 5 (Strongly Agree)
Measured: Weeks 3 (mid-intervention assessment), 6 (post-intervention assessment))
Hr-QOL scales using SS-QOL (Stroke specific Quality of Life scale)
Quality of life scale specific to stroke patients, minimum 49, maximum 245; with higher scores indicating better function.
Measured: Weeks 0 (baseline), 6 (post-intervention assessment), 12 (1st follow-up assessment), 24 (last follow-up assessment)
Box and Block Test (BBT)
Measures unilateral gross manual dexterity.
Measured: Weeks 0 (baseline), 3 (mid-intervention assessment), 6 (post-intervention assessment), 12 (1st follow-up assessment), 24 (last follow-up assessment)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 May 2024
- Study start31 Jul 2024
- Primary completion5 Jun 2026
- Study completion5 Jun 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for StrokeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- The study design is a pilot, clinical feasibility, assessor-blinded trial to evaluate the feasibility of Home RehabGym concept through deployment of three rehabilitation devices at patients' homes: MyoPanda, H-Man and ReHandyBot. During the 6 weeks training at home phase, patients will be provided with two devices at any one time: with only the MyoPanda being used by the patient for 6 weeks. The H-Man and ReHandyBot will stay with the patient for 3 weeks (i.e. 21 days) each and then alternate.
- Masking
- None (open label)
- Enrolment
- 29 participants (actual)
Sponsor and investigators
- Lead sponsor
- Tan Tock Seng Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Kuah Wee Keong Christopher, Principal investigator, Tan Tock Seng Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06406569
- Sponsor's protocol ID
- DSRB 2023/00527
- Acronym
- Home RehabGym
- Status last verified
- Oct 2026
- First submitted
- 6 May 2024
- Last updated
- 7 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Kager S, Cheng HJ, Kuah CWK, Samkharadze T, Lin HP, Ng CY, Plunkett TK, Lee S, Devi N, Sumartono F, Lu I, Sidarta A, Lie E, Hungerbuehler I, Chong D, Sinha AK, Tang CO, Matchar D, Devittori G, Kanzler C, Hussain A, Noronha B, Azhar M, Aguirre-Ollinger G, Gassert R, Chua KSG, Wenderoth N, Lambercy O. Technology-Assisted Rehabilitation Gym for at-home Training (TARGeT) for stroke survivors: A study protocol for evaluating feasibility, safety, usability, clinical benefit, and costs. PLoS One. 2026 Sep 2;21(9):e0355160. doi: 10.1371/journal.pone.0355160. eCollection 2026.
PubMed 42685043
Study at a glance
From the registry record, last updated by the sponsor on 7 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Home RehabGym: a Qualitative and Usability Evaluation of Advanced Technologies for Home Upper Limb Neurorehabilitation Post-stroke
- ClinicalTrials.gov ID
- NCT06406569
- Acronym / sponsor ID
- Home RehabGym / DSRB 2023/00527
- Conditions
- Stroke
- Keywords
- Technology-aided, Upper limb rehabilitation
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 29 participants (actual)
- Lead sponsor
- Tan Tock Seng HospitalUniversity, hospital or other
- Study start
- 31 Jul 2024 (actual)
- Primary completion
- 5 Jun 2026 (actual)
- Study completion
- 5 Jun 2026 (actual)
- First posted
- 9 May 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Due to limited resources such as the low therapist to patient ratio or high costs associated to rehabilitation therapy, providing higher therapy dose to patients after discharge is highly challenging. This often results in non-use of the impaired limb as a result of the decreased therapy dose, causing partial loss of the functional improvements previously gained during early rehabilitation.
In this study, the investigators plan to pilot the HomeRehab Gym concept via the deployment of three rehabilitation devices at patients' homes: MyoPanda, H-Man and ReHandyBot.
Detailed description
Previous research has proven that technology-aided upper limb rehabilitation is non-inferior in terms of feasibility and efficacy when compared to conventional therapy in stroke patients. These rehabilitation devices can be set up as a 'rehabilitation gym' (RehabGym), where patients can interact with several devices that target different body and rehabilitation domains and, thus allows for a holistic and complementary therapy.
Despite recent studies having shown that training with a RehabGym under reduced supervision in a hospital is not only feasible but also equally beneficial in terms of clinical outcomes, however, a RehabGym has never been set up at a patient's home to the best of our knowledge.
This study aims to investigate the feasibility and safety of a RehabGym at home concept using three different upper-limb technologies (H-Man, ReHandyBot, MyoPanda) that are established, clinically tested and allow for on-demand therapy. Objective measures of clinical efficacy will also be examined, and cost-analysis to determine the economic feasibility of a commercial implementation of RehabGym at home in the future will be performed.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- The study design is a pilot, clinical feasibility, assessor-blinded trial to evaluate the feasibility of Home RehabGym concept through deployment of three rehabilitation devices at patients' homes: MyoPanda, H-Man and ReHandyBot. During the 6 weeks training at home phase, patients will be provided with two devices at any one time: with only the MyoPanda being used by the patient for 6 weeks. The H-Man and ReHandyBot will stay with the patient for 3 weeks (i.e. 21 days) each and then alternate.
| Arm | Type | Receives |
|---|---|---|
| Home Robotics Upper Limb Training | Other | Device: H-Man Robot, Device: ReHandyBot, Device: MyoPandaThe patients will first familiarize in the clinic with the 3 devices (H-MAN, ReHandyBot and MyoPanda) with initial assistance of the therapists and then take the devices home for independent, self-administered training under caregiver supervision. During the 6 weeks training (home phase), patients will be provided with two devices at any one time: with only the MyoPanda being used by the patient for 6 weeks. The H-MAN and ReHandyBot will stay with the patient for 3 weeks (i.e., 21 days) each. |
Who may qualify
- Ages
- 21 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Clinical stroke (ischaemic or haemorrhagic) confirmed by admitting doctors and CT, CT angiography or MRI brain imaging
- Age 21 to 80 years, both males and females
- At least 28 days post-stroke
- Upper limb motor impairment of Fugl-Meyer Assessment (FMA) scale 20 to 50
- Montreal Cognitive Assessment (MoCA) > 21/30
Key exclusion criteria (13 listed)
- Functional impairment of the upper limb due to other pathologies
- Medical conditions incompatible with research participation: uncontrolled medical illnesses (hypertension or diabetes, ischaemic heart disease, congestive heart failure, bronchial asthma, severe /untreated depression, agitation, end stage renal/liver/heart/lung failure, unresolved cancers)
- Anticipated life expectancy of less than 6 months
- Pacemakers and other active implants
- Active seizures within 3 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| H-Man RobotThe HMAN is certified as a CE class 2A upper limb rehabilitation robot suitable for hospital, clinic and home-based use in 2020 by Health Sciences Authority, Singapore. It has since been employed in post-stroke neurorehabilitation therapy and assessment of sensorimotor functions in stroke patients. | Device | Home Robotics Upper Limb Training |
| ReHandyBotReHandyBot is the portable version of ReHapticKnob a robot developed at ETH Zurich that provides neurocognitive therapy, focusing on hand opening and closing movements as well as prono-supination of the forearm. | Device | Home Robotics Upper Limb Training |
| MyoPandaMyoPanda is a passive wrist/hand device which patients use to train the hand and wrist function by controlling a virtual avatar with EMG activity measures. | Device | Home Robotics Upper Limb Training |
Primary outcome
Compliance Rates
Time frame: Through study's data collection period, up to 2 years.
Using cloud data from vendor, time (min/hours) of robot (H-Man, ReHandyBot, MyoPanda) usage
5 secondary outcomes
Fugl Meyer Motor Assessment (FMA)
Time frame: Weeks 0 (baseline), 3 (mid-intervention assessment), 6 (post-intervention assessment), 12 (1st follow-up assessment), 24 (last follow-up assessment)
Action Research Arm Test (ARAT)
Time frame: Weeks 0 (baseline), 3 (mid-intervention assessment), 6 (post-intervention assessment), 12 (1st follow-up assessment), 24 (last follow-up assessment)
System Usability Scale (SUS)
Time frame: Weeks 3 (mid-intervention assessment), 6 (post-intervention assessment))
Hr-QOL scales using SS-QOL (Stroke specific Quality of Life scale)
Time frame: Weeks 0 (baseline), 6 (post-intervention assessment), 12 (1st follow-up assessment), 24 (last follow-up assessment)
Box and Block Test (BBT)
Time frame: Weeks 0 (baseline), 3 (mid-intervention assessment), 6 (post-intervention assessment), 12 (1st follow-up assessment), 24 (last follow-up assessment)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Oct 2026.
- Derived from this study: PubMed 42685043Kager S, Cheng HJ, Kuah CWK, Samkharadze T, Lin HP, Ng CY, Plunkett TK, Lee S, Devi N, Sumartono F, Lu I, Sidarta A, Lie E, Hungerbuehler I, Chong D, Sinha AK, Tang CO, Matchar D, Devittori G, Kanzler C, Hussain A, Noronha B, Azhar M, Aguirre-Ollinger G, Gassert R, Chua KSG, Wenderoth N, Lambercy O. Technology-Assisted Rehabilitation Gym for at-home Training (TARGeT) for stroke survivors: A study protocol for evaluating feasibility, safety, usability, clinical benefit, and costs. PLoS One. 2026 Sep 2;21(9):e0355160. doi: 10.1371/journal.pone.0355160. eCollection 2026.
- Individual participant dataSharing planned: No
Related trials for Stroke
Not yet recruiting
Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke
Acute Ischemic Stroke
RecruitingObservational study
ELATE Study: Evaluating Large-vessel Acute Thrombectomy in Extended Time Window
Acute Ichemic Stroke
Recruiting
Web-Based Tele-Rehabilitation Using Action Observation and Mirror Therapy for Subacute Stroke: A Randomized Controlled Trial
Stroke, Upper Extremity Paresis
Recruiting
Early Motor-Cognitive Integrative Training on Cognitive and Motor Performance in Patients With Aneurysmal Subarachnoid Hemorrhage
Subarachnoid Aneurysm Hemorrhage
Not yet recruiting
Selective Intra-Arterial Hypothermia After Endovascular Treatment for Acute Basilar Artery Occlusion
Acute Ischemic Stroke, Basilar Artery Occlusion
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kuah Wee Keong Christopher principal investigator
Tan Tock Seng Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing H-Man Robot, ReHandyBot and MyoPanda in people with Stroke, run by Tan Tock Seng Hospital at 1 site in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Compliance Rates (time frame: Through study's data collection period, up to 2 years.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06406569, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Oct 2026.